Extrapharm Tilff SRL
1.3 FTEThe score of Extrapharm Tilff shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +7 % Total assets +173 % Headcount (avg FTE) -24 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Extrapharm Tilff's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −72,704 € | ||||
| Equity | 320,924 € | ||||
| Cash | 130,209 € | ||||
| EBITDA | 31,273 € | ||||
| Total assets | €1.91m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jun 2026
- Year ended 31 Dec 2024filed on 24 Nov 2025
- Year ended 31 Dec 2023filed on 04 Jul 2024
- Year ended 31 Dec 2022filed on 31 Aug 2023
- Year ended 31 Dec 2021filed on 15 Jul 2022
Extrapharm Tilff's financial analysis
- Solvency16.8%sector median: 41.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Extrapharm Tilff
Extrapharm Tilff's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0827.434.447
- VAT number
- BE0827434447
- Peppol
- Registered · 0208:0827434447 · as of 22 Oct 2026
- Legal form
- SRL
- Incorporated
- 01 Jul 2010
- Registered office
- 4130 Esneux
- Size
- Micro · 1.3 FTE
- Latest accounts
- 2025 · filed on 16 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Extrapharm Tilff (SRL) has been based in Esneux since 2010, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 72,704 € and equity of 320,924 €; its revenue is not published. With 1.3 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 16.8%, below the median of its sector (41.6%).
Companies similar to Extrapharm Tilff
Companies in the same business, of comparable size and area, outside its group.
- Geassocieerde Apotheek Schoten Retail sale of pharmaceutical products Schoten · balance sheet €1.91m
- Apotheek Clijsters Retail sale of pharmaceutical products Pelt · balance sheet €1.91m
- Ludaphar Retail sale of pharmaceutical products Beauvechain · balance sheet €1.91m
- Opniphar Retail sale of pharmaceutical products Buggenhout · balance sheet €1.90m
- Virco Pharma Retail sale of pharmaceutical products Hoeilaart · balance sheet €1.92m
- Pharmacie Herman M.C. Retail sale of pharmaceutical products Charleroi · balance sheet €1.92m
- Pharmayou Waremme Saint-Eloi Retail sale of pharmaceutical products Waremme · balance sheet €1.89m
- Medicels Retail sale of pharmaceutical products Kapellen · balance sheet €1.93m
Frequently asked questions about Extrapharm Tilff
What is the revenue of Extrapharm Tilff?
Extrapharm Tilff files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Extrapharm Tilff?
In Belgium, the VAT number is the company number prefixed with BE: BE0827434447 for Extrapharm Tilff, if the company is VAT-registered. Its company number (CBE) is 0827.434.447.
Where is the registered office of Extrapharm Tilff?
According to the CBE register, the registered office of Extrapharm Tilff is in 4130 Esneux.
What is the equity of Extrapharm Tilff?
At the close of the 2025 financial year, the equity of Extrapharm Tilff amounts to 320,924 €, a solvency of 16.8% of total assets.
How many people work at Extrapharm Tilff?
1.3 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Extrapharm Tilff?
The register lists 6 active mandates at Extrapharm Tilff. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Extrapharm Tilff
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →